Capital Bank & Trust Co grew its stake in Shire PLC (NASDAQ:SHPG) by 42.7% in the third quarter, Holdings Channel reports. The fund owned 1,070 shares of the biopharmaceutical company’s stock after acquiring an additional 320 shares during the period. Capital Bank & Trust Co’s holdings in Shire were worth $194,000 at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in SHPG. Cornerstone Wealth Management LLC bought a new stake in shares of Shire in the 2nd quarter valued at about $145,000. Linscomb & Williams Inc. bought a new stake in Shire during the 2nd quarter worth approximately $210,000. Greenleaf Trust increased its stake in Shire by 32.0% during the 2nd quarter. Greenleaf Trust now owns 3,194 shares of the biopharmaceutical company’s stock worth $539,000 after purchasing an additional 774 shares in the last quarter. SG Americas Securities LLC increased its stake in Shire by 1,634.4% during the 2nd quarter. SG Americas Securities LLC now owns 193,547 shares of the biopharmaceutical company’s stock worth $32,671,000 after purchasing an additional 182,388 shares in the last quarter. Finally, Bellevue Group AG increased its stake in Shire by 11.7% during the 2nd quarter. Bellevue Group AG now owns 65,292 shares of the biopharmaceutical company’s stock worth $11,021,000 after purchasing an additional 6,857 shares in the last quarter. 20.49% of the stock is owned by institutional investors.
NASDAQ SHPG opened at $169.66 on Wednesday. Shire PLC has a 52-week low of $123.73 and a 52-week high of $182.47. The company has a debt-to-equity ratio of 0.36, a current ratio of 0.92 and a quick ratio of 0.51. The company has a market cap of $52.74 billion, a P/E ratio of 11.20, a price-to-earnings-growth ratio of 1.56 and a beta of 1.01.
A number of analysts recently issued reports on SHPG shares. BidaskClub raised Shire from a “hold” rating to a “buy” rating in a research note on Wednesday, October 24th. Royal Bank of Canada set a $195.00 target price on Shire and gave the stock a “buy” rating in a research note on Tuesday, October 23rd. B. Riley reissued a “buy” rating on shares of Shire in a research note on Tuesday, December 4th. Zacks Investment Research reissued a “hold” rating on shares of Shire in a research note on Thursday, November 15th. Finally, ValuEngine raised Shire from a “sell” rating to a “hold” rating in a research note on Friday, September 21st. Ten investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $201.11.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Recommended Story: Why is Cost of Capital Important?
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.